Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026
Company Drug

Vcanbio’s VUM02 Secures NMPA Approval and FDA ODD for Cirrhosis and aGvHD

Fineline Cube Dec 17, 2024

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced significant progress for...

Company

Novo Nordisk Invests DKK 8.5 Billion in New Odense Manufacturing Facility

Fineline Cube Dec 17, 2024

Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) is making a significant investment in its...

Company Drug

Johnson & Johnson Submits sBLA to FDA for Simponi in Pediatric Ulcerative Colitis

Fineline Cube Dec 17, 2024

US pharmaceutical major Johnson & Johnson (J&J, NYSE: JNJ) has announced the submission of a...

Company Drug

J&J’s SC Amivantamab Faces Complete Response Letter from FDA for NSCLC Treatment

Fineline Cube Dec 17, 2024

Johnson & Johnson (J&J, NYSE: JNJ) has announced that the Biologics License Application (BLA) filed...

Company Drug

Grand Pharmaceutical’s GPN01768 Accepted for Review by NMPA for Demodex Blepharitis Treatment

Fineline Cube Dec 17, 2024

Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced that the National Medical Products Administration...

Company Drug

Jiangsu Hengrui’s Trastuzumab Rezetecan on Track for NMPA’s Breakthrough Therapy Designation

Fineline Cube Dec 17, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Abbisko Therapeutics Receives NMPA Approval for Irpagratinib Regulatory Study

Fineline Cube Dec 17, 2024

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...

Company Drug

Vocabria Receives Positive CHMP Opinion for HIV Treatment in Adolescents

Fineline Cube Dec 17, 2024

GSK plc (NYSE: GSK) has announced that ViiV Healthcare, an HIV specialist majority owned by...

Company Drug

GSK’s Jemperli Receives Positive CHMP Opinion for Endometrial Cancer Indication Extension

Fineline Cube Dec 17, 2024

The UK-based pharmaceutical giant GSK (NYSE: GSK) has received a positive opinion from the European...

Company Drug

GSK’s Jemperli Receives FDA Breakthrough Therapy Designation for Rectal Cancer Treatment

Fineline Cube Dec 17, 2024

UK-based pharmaceutical giant GSK (NYSE: GSK) has announced that it has received Breakthrough Therapy Designation...

Company Drug

CanSino Biologics’ DTcP Vaccine for Infants and Young Children Accepted by NMPA for Review

Fineline Cube Dec 17, 2024

China-based vaccines specialist CanSino Biologics Inc. (HKG: 6185) has announced that the National Medical Products...

Company Deals

MicroPort NeuroTech Leads Investment Fund to Advance Brain Science Industry

Fineline Cube Dec 17, 2024

China-based MicroPort NeuroTech Limited (HKG: 2172) has announced its commitment to invest RMB 200 million...

Company Deals

Candid Therapeutics Expands TCE Portfolio with Strategic Partnerships in Autoimmune Disease Treatment

Fineline Cube Dec 17, 2024

US-based Candid Therapeutics Inc. is fulfilling its ambition to become a leader in advancing T-cell...

Company Drug

EMA Grants PRIME Designation to Hansoh Pharmaceutical’s HS-20093 in Collaboration with GSK

Fineline Cube Dec 17, 2024

The European Medicines Agency (EMA) has conferred Priority Medicines (PRIME) designation to HS-20093 (GSK5764227), a...

Company Deals

Bio-Thera Solutions Expands License Deal with SteinCares for Latin American Market

Fineline Cube Dec 17, 2024

China-based Bio-Thera Solutions (SHA: 688177) has announced the addition of a third biosimilar to its...

Company Drug

European CHMP Supports Conditional Approval of MSD’s Welireg for VHL Disease and RCC

Fineline Cube Dec 16, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the European Medicines Agency’s Committee...

Company Drug

EMA’s CHMP Recommends Approval of Bayer’s Acoramidis for ATTR-CM Treatment

Fineline Cube Dec 16, 2024

Bayer’s (ETR: BAYN) acoramidis has received a positive recommendation from the Committee for Medicinal Products...

Policy / Regulatory

Guangdong Province Releases List of Urgent Clinical Drugs and Devices for GBA Cities

Fineline Cube Dec 16, 2024

The medical products administration and health commission of Guangdong province have released a list of...

Company Drug

Sanofi’s Tolebrutinib Earns FDA Breakthrough Designation for Non-Relapsing Secondary Progressive MS

Fineline Cube Dec 16, 2024

Sanofi (NASDAQ: SNY) has announced that the US Food and Drug Administration (FDA) has granted...

Company Medical Device

Roche’s cobas 6800/8800 Systems 2.0 Earn CE Certification, Set for US Market Entry

Fineline Cube Dec 16, 2024

Global healthcare company Roche (SWX: ROG) has announced that its state-of-the-art cobas 6800/8800 Systems 2.0...

Posts pagination

1 … 185 186 187 … 606

Recent updates

  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
  • RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
  • Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.